Stefan D. Anker

Anker studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993) and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998.{{cn|date=June 2024}}

Anker has had teaching appointments in the UK, Germany, Australia and Italy.{{Cite news|url=http://2016.icimeeting.com/staff/stefan-d-anker/|title=ICI Meeting 2016 {{!}} Staff Members {{!}} Stefan D. Anker {{!}} Innovations|access-date=2017-05-17|language=en-US}}

His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy{{Cite news|url=https://www.prevention.com/health/wasting-syndrome|title=This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know|date=2017-09-27|work=Prevention|access-date=2017-10-04|language=en}} in CHF, ageing, sarcopenia and cancer.{{Cite web|url=https://onlinelibrary.wiley.com/page/journal/1353921906009/homepage/EditorialBoard.html|title=Journal of Cachexia, Sarcopenia and Muscle|website=Wiley Online Library}}

Anker serves on the editorial boards of European Heart Journal{{Cite web |title=European Heart Journal |url=https://academic.oup.com/eurheartj/pages/Editorial_Board |access-date=2024-06-21 |website=academic.oup.com}} and European Journal of Heart Failure.{{Cite web | url=http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1879-0844/homepage/EditorialBoard.html | doi=10.1002/(ISSN)1879-0844| title=European Journal of Heart Failure| s2cid=115560449}} He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle{{Cite web|url=http://www.jcsm.info/index.php/en/|title=Home|website=www.jcsm.info|language=en-gb|access-date=2017-05-17}} and of ESC Heart Failure, which is the first open access heart failure journal.{{Cite journal |title=ESC Heart Failure |journal=ESC Heart Failure |language=en |doi=10.1002/(issn)2055-5822|doi-access=free }}

Anker has won two American Heart Association Young Investigator AwardsAHA Samuel A Levine Young Investigator Award (Clinical Cardiology) 1st Prize for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure, November 2000.AHA Samuel A Levine Young Investigator Award (Clinical Cardiology) 1st Prize; for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia, November 2006. and has obtained two National Institutes of Health (NIH) grants (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial),{{Cite report |url=https://clinicaltrials.gov/study/NCT00041938 |title=Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial |last=Homma |first=Shunichi |date=2014-08-29 |publisher=clinicaltrials.gov |issue=NCT00041938}} two grants from the EU's Seventh Framework Programme for Research (FP7), and one Innovative Medicines Initiative / Horizon 2020 grant.{{Cite web|url=https://www.escardio.org/Congresses-&-Events/Heart-Failure/Scientific-Programme/hfa-career-cafe|title=HFA Career Cafe 2017|website=www.escardio.org|access-date=2017-05-17}}

Anker has been a member of the German Cardiac Society and of the European Society of Cardiology (ESC) since 1995. He is currently{{when?|date=June 2024}} vice president of the ESC in charge of 'National Cardiac Societies and Communications.'{{cn|date=June 2024}} He has been serving on the board of the ESC since 2012.{{Cite web|url=https://www.escardio.org/The-ESC/Governance/ESC-Board|title=ESC Board|website=www.escardio.org|access-date=2017-05-17}} In addition, he has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006. He was HFA President between 2012 and 2014 and he chairs the HFA committee on regulatory affairs.{{Cite web|url=https://www.escardio.org/Sub-specialty-communities/Heart-Failure-Association-of-the-ESC-(HFA)/About/committees-and-study-groups-of-the-heart-failure-association-of-the-esc|title=Committees and Study Groups of the Heart Failure Association of the ESC|website=www.escardio.org|access-date=2017-05-17}}

Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).{{Cite news|url=http://society-scwd.org/scwd-board/|title=Details of the SCWD board members|work=Sarcopenia, Cachexia and Wasting Disorders|access-date=2017-05-17|language=en-GB}}{{Cite news|url=http://society-scwd.org/wasting-disorders/|title=SCWD - Sarcopenia, Cachexia and Wasting Disorders|work=Sarcopenia, Cachexia and Wasting Disorders|access-date=2017-05-17|language=en-GB}}

Anker has authored more than 700 original papers, reviews, and editorials. Total citations exceed 46,000, including over 50 papers with more than 200 citations. He has an h-index of 104.{{PubMedAuthorSearch|Anker|SD}}Scopus, March 2017, https://www.scopus.com/authid/detail.uri?authorId=56223993400

• {{cite journal| pmid=9107242 | doi=10.1016/S0140-6736(96)07015-8 | volume=349 | issue=9058 | title=Wasting as independent risk factor for mortality in chronic heart failure | date=April 1997 | journal=Lancet | pages=1050–3 | last1 = Anker | first1 = SD | last2 = Ponikowski | first2 = P | last3 = Varney | first3 = S | s2cid=27285694 | display-authors = et al}}
• {{cite journal| pmid=9244221 | volume=96 | issue=2 | title=Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia | year=1997 | journal=Circulation | pages=526–34 | last1 = Anker | first1 = SD | last2 = Chua | first2 = TP | last3 = Ponikowski | first3 = P | last4 = Harrington | first4 = D | last5 = Swan | first5 = JW | last6 = Kox | first6 = WJ | last7 = Poole-Wilson | first7 = PA | last8 = Coats | first8 = AJ | doi=10.1161/01.cir.96.2.526}}
• {{cite journal| pmid=10359409 | doi=10.1016/S0140-6736(98)09286-1 | volume=353 | issue=9167 | title=Endotoxin and immune activation in chronic heart failure: a prospective cohort study | year=1999 | journal=Lancet | pages=1838–42 | last1 = Niebauer | first1 = J | last2 = Volk | first2 = HD | last3 = Kemp | first3 = M | last4 = Dominguez | first4 = M | last5 = Schumann | first5 = RR | last6 = Rauchhaus | first6 = M | last7 = Poole-Wilson | first7 = PA | last8 = Coats | first8 = AJ | last9 = Anker | first9 = SD| s2cid=34183643 }}
• {{cite journal| pmid=11036910 | doi=10.1016/S0140-6736(00)02690-8 | volume=356 | issue=9233 | title=The endotoxin-lipoprotein hypothesis | year=2000 | journal=Lancet | pages=930–3 | last1 = Rauchhaus | first1 = M | last2 = Coats | first2 = AJ | last3 = Anker | first3 = SD| s2cid=27005597 }}
• {{cite journal| pmid=12672310 | doi=10.1016/S0140-6736(03)12892-9 | volume=361 | issue=9363 | title=Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study | date=March 2003 | journal=Lancet | pages=1077–83 | last1 = Anker | first1 = SD | last2 = Negassa | first2 = A | last3 = Coats | first3 = AJ | s2cid=24682546 | display-authors =et al}}
• {{cite journal| pmid=12707250 | doi=10.1161/01.CIR.0000065637.10517.A0 | volume=107 | issue=15 | title=Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging | year=2003 | journal=Circulation | pages=1991–7 | last1 = Anker | first1 = SD | last2 = Doehner | first2 = W | last3 = Rauchhaus | first3 = M | last4 = Sharma | first4 = R | last5 = Francis | first5 = D | last6 = Knosalla | first6 = C | last7 = Davos | first7 = CH | last8 = Cicoira | first8 = M | last9 = Shamim | first9 = W | last10 = Kemp | first10 = M | last11 = Segal | first11 = R | last12 = Osterziel | first12 = KJ | last13 = Leyva | first13 = F | last14 = Hetzer | first14 = R | last15 = Ponikowski | first15 = P | last16 = Coats | first16 = AJ| s2cid=13323584 | doi-access = free }}
• {{cite journal | last1 = Anker | first1 = SD | last2 = Comin Colet | first2 = J | last3 = Filippatos | first3 = G | display-authors = et al | year = 2009 | title = Ferric carboxymaltose in patients with heart failure and iron deficiency | url = http://lup.lub.lu.se/record/1511843| journal = N Engl J Med | volume = 361 | issue = 25| pages = 2436–48 | pmid = 19920054 | doi = 10.1056/NEJMoa0908355 | hdl = 11268/1142 | s2cid = 1755624 | hdl-access = free }}
• {{cite journal| pmid=20447528 | doi=10.1016/j.jacc.2010.02.025 | volume=55 | issue=19 | title=Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial | year=2010 | journal=J Am Coll Cardiol | pages=2062–76 | last1 = Maisel | first1 = A | last2 = Mueller | first2 = C | last3 = Nowak | first3 = R | last4 = Peacock | first4 = WF | last5 = Landsberg | first5 = JW | last6 = Ponikowski | first6 = P | last7 = Mockel | first7 = M | last8 = Hogan | first8 = C | last9 = Wu | first9 = AH | last10 = Richards | first10 = M | last11 = Clopton | first11 = P | last12 = Filippatos | first12 = GS | last13 = Di Somma | first13 = S | last14 = Anand | first14 = I | last15 = Ng | first15 = L | last16 = Daniels | first16 = LB | last17 = Neath | first17 = SX | last18 = Christenson | first18 = R | last19 = Potocki | first19 = M | last20 = McCord | first20 = J | last21 = Terracciano | first21 = G | last22 = Kremastinos | first22 = D | last23 = Hartmann | first23 = O | last24 = von Haehling | first24 = S | last25 = Bergmann | first25 = A | last26 = Morgenthaler | first26 = NG | last27 = Anker | first27 = SD| doi-access = }}
• {{cite journal| pmid=21444883 | doi=10.1161/CIRCULATIONAHA.111.018473 | volume=123 | issue=17 | title=Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study | year=2011 | journal=Circulation | pages=1873–80 | last1 = Koehler | first1 = F | last2 = Winkler | first2 = S | last3 = Schieber | first3 = M | last4 = Sechtem | first4 = U | last5 = Stangl | first5 = K | last6 = Böhm | first6 = M | last7 = Boll | first7 = H | last8 = Baumann | first8 = G | last9 = Honold | first9 = M | last10 = Koehler | first10 = K | last11 = Gelbrich | first11 = G | last12 = Kirwan | first12 = BA | last13 = Anker | first13 = SD| s2cid=11473865 | doi-access = free }}
• {{cite journal| pmid=21856487 | doi=10.1016/S0140-6736(11)61229-4 | volume=378 | issue=9792 | title=Telemedicine and remote management of patients with heart failure | year=2011 | journal=Lancet | pages=731–9 | last1 = Anker | first1 = SD | last2 = Koehler | first2 = F | last3 = Abraham | first3 = WT| s2cid=10977216 }}
• {{cite journal| pmid=22300693 | doi=10.1016/j.jacc.2011.10.880 | volume=59 | issue=6 | title=Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial | year=2012 | journal=J Am Coll Cardiol | pages=585–92 | last1 = von Haehling | first1 = S | last2 = Schefold | first2 = JC | last3 = Jankowska | first3 = EA | last4 = Springer | first4 = J | last5 = Vazir | first5 = A | last6 = Kalra | first6 = PR | last7 = Sandek | first7 = A | last8 = Fauler | first8 = G | last9 = Stojakovic | first9 = T | last10 = Trauner | first10 = M | last11 = Ponikowski | first11 = P | last12 = Volk | first12 = HD | last13 = Doehner | first13 = W | last14 = Coats | first14 = AJ | last15 = Poole-Wilson | first15 = PA | last16 = Anker | first16 = SD| doi-access = free }}
• {{cite journal| pmid=22551105 | doi=10.1056/NEJMoa1202299 | pmc=3723382 | volume=366 | issue=20 | title=Warfarin and aspirin in patients with heart failure and sinus rhythm | year=2012 | journal=N Engl J Med | pages=1859–69 | last1 = Homma | first1 = S | last2 = Thompson | first2 = JL | last3 = Pullicino | first3 = PM | last4 = Levin | first4 = B | last5 = Freudenberger | first5 = RS | last6 = Teerlink | first6 = JR | last7 = Ammon | first7 = SE | last8 = Graham | first8 = S | last9 = Sacco | first9 = RL | last10 = Mann | first10 = DL | last11 = Mohr | first11 = JP | last12 = Massie | first12 = BM | last13 = Labovitz | first13 = AJ | last14 = Anker | first14 = SD | last15 = Lok | first15 = DJ | last16 = Ponikowski | first16 = P | last17 = Estol | first17 = CJ | last18 = Lip | first18 = GY | last19 = Di Tullio | first19 = MR | last20 = Sanford | first20 = AR | last21 = Mejia | first21 = V | last22 = Gabriel | first22 = AP | last23 = del Valle | first23 = ML | last24 = Buchsbaum | first24 = R}}
• {{cite journal| pmid=25176939 | doi=10.1093/eurheartj/ehu385 | pmc=4359359 | volume=36 | issue=11 | title=Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† | year=2015 | journal=Eur Heart J | pages=657–68 | last1 = Ponikowski | first1 = P | last2 = van Veldhuisen | first2 = DJ | last3 = Comin-Colet | first3 = J | last4 = Ertl | first4 = G | last5 = Komajda | first5 = M | last6 = Mareev | first6 = V | last7 = McDonagh | first7 = T | last8 = Parkhomenko | first8 = A | last9 = Tavazzi | first9 = L | last10 = Levesque | first10 = V | last11 = Mori | first11 = C | last12 = Roubert | first12 = B | last13 = Filippatos | first13 = G | last14 = Ruschitzka | first14 = F | last15 = Anker | first15 = SD}}

Anker has participated in and chaired several consensus meeting and guidelines committees:

• Chair, ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. (Anker et al., Clin Nutr 2009)
• Co-chair, Consensus Group “The definition of Cachexia” (Evans et al., Clinical Nutrition 2008){{Cite journal|last1=Evans|first1=William J.|last2=Morley|first2=John E.|last3=Argilés|first3=Josep|last4=Bales|first4=Connie|last5=Baracos|first5=Vickie|last6=Guttridge|first6=Denis|last7=Jatoi|first7=Aminah|last8=Kalantar-Zadeh|first8=Kamyar|last9=Lochs|first9=Herbert|date=2008-12-01|title=Cachexia: a new definition|journal=Clinical Nutrition (Edinburgh, Scotland)|volume=27|issue=6|pages=793–799|doi=10.1016/j.clnu.2008.06.013|issn=1532-1983|pmid=18718696|s2cid=206821612 }}
• AHA Consensus Group “State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association.” (Riegel et al., Circulation 2009){{Cite journal|last1=Riegel|first1=Barbara|last2=Moser|first2=Debra K.|last3=Anker|first3=Stefan D.|last4=Appel|first4=Lawrence J.|last5=Dunbar|first5=Sandra B.|last6=Grady|first6=Kathleen L.|last7=Gurvitz|first7=Michelle Z.|last8=Havranek|first8=Edward P.|last9=Lee|first9=Christopher S.|date=2009-09-22|title=State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association|journal=Circulation|volume=120|issue=12|pages=1141–1163|doi=10.1161/CIRCULATIONAHA.109.192628|issn=1524-4539|pmid=19720935|citeseerx=10.1.1.335.9667|s2cid=6973440 }}
• ADQI 7 Consensus Group “Cardio-Renal Syndromes” (Ronco et al., Eur Heart J 2010){{Cite journal|last1=Ronco|first1=Claudio|last2=McCullough|first2=Peter|last3=Anker|first3=Stefan D.|last4=Anand|first4=Inder|last5=Aspromonte|first5=Nadia|last6=Bagshaw|first6=Sean M.|last7=Bellomo|first7=Rinaldo|last8=Berl|first8=Tomas|last9=Bobek|first9=Ilona|date=2017-05-17|title=Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative|journal=European Heart Journal|volume=31|issue=6|pages=703–711|doi=10.1093/eurheartj/ehp507|issn=0195-668X|pmc=2838681|pmid=20037146}}
• Co-chair, Consensus Group “Endpoints for Cachexia Trials & Nutrition for Cachexia and Sarcopenia” (Morley et al., JAMDA 2010){{Cite journal|last1=Argilés|first1=Josep M.|last2=Anker|first2=Stefan D.|last3=Evans|first3=William J.|last4=Morley|first4=John E.|last5=Fearon|first5=Ken C. H.|last6=Strasser|first6=Florian|last7=Muscaritoli|first7=Maurizio|last8=Baracos|first8=Vicky E.|date=2010-05-01|title=Consensus on cachexia definitions|journal=Journal of the American Medical Directors Association|volume=11|issue=4|pages=229–230|doi=10.1016/j.jamda.2010.02.004|issn=1538-9375|pmid=20439040}}
• Nutritional recommendations for the management of sarcopenia. Co-chair. (Morley el al., JAMDA 2010){{Cite journal|last1=Morley|first1=John E.|last2=Argiles|first2=Josep M.|last3=Evans|first3=William J.|last4=Bhasin|first4=Shalender|last5=Cella|first5=David|last6=Deutz|first6=Nicolaas E. P.|last7=Doehner|first7=Wolfram|last8=Fearon|first8=Ken C. H.|last9=Ferrucci|first9=Luigi|date=2017-05-17|title=Nutritional Recommendations for the Management of Sarcopenia|journal=Journal of the American Medical Directors Association|volume=11|issue=6|pages=391–396|doi=10.1016/j.jamda.2010.04.014|issn=1525-8610|pmc=4623318|pmid=20627179}}
• “Definition and classification of cancer cachexia” (Fearon et al. Lancet Oncol 2011){{Cite journal|last1=Fearon|first1=Kenneth|last2=Strasser|first2=Florian|last3=Anker|first3=Stefan D.|last4=Bosaeus|first4=Ingvar|last5=Bruera|first5=Eduardo|last6=Fainsinger|first6=Robin L.|last7=Jatoi|first7=Aminah|last8=Loprinzi|first8=Charles|last9=MacDonald|first9=Neil|date=2011-05-01|title=Definition and classification of cancer cachexia: an international consensus|journal=The Lancet. Oncology|volume=12|issue=5|pages=489–495|doi=10.1016/S1470-2045(10)70218-7|issn=1474-5488|pmid=21296615}}
• ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (McMurray et al., EHJ 2012){{Cite journal|last1=McMurray|first1=John J. V.|last2=Adamopoulos|first2=Stamatis|last3=Anker|first3=Stefan D.|last4=Auricchio|first4=Angelo|last5=Böhm|first5=Michael|last6=Dickstein|first6=Kenneth|last7=Falk|first7=Volkmar|last8=Filippatos|first8=Gerasimos|last9=Fonseca|first9=Cândida|date=2012-07-01|title=ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC|journal=European Heart Journal|volume=33|issue=14|pages=1787–1847|doi=10.1093/eurheartj/ehs104|issn=1522-9645|pmid=22611136|doi-access=free}}
• HFA/WGTE of ESC Consensus on thromboembolism & anti-thrombotic therapy in heart failure with sinus rhythm (Lip et al. Eur J HF 2012){{Cite journal|last1=Lip|first1=Gregory Y. H.|last2=Ponikowski|first2=Piotr|last3=Andreotti|first3=Felicita|last4=Anker|first4=Stefan D.|last5=Filippatos|first5=Gerasimos|last6=Homma|first6=Shunichi|last7=Morais|first7=Joao|last8=Pullicino|first8=Patrick|last9=Rasmussen|first9=Lars H.|date=2012-07-01|title=Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis|journal=European Journal of Heart Failure|volume=14|issue=7|pages=681–695|doi=10.1093/eurjhf/hfs073|issn=1879-0844|pmid=22611046|s2cid=20956860|doi-access=free}}
• ESH/ESC Guidelines for the management of arterial hypertension. Reviewer. (Mancia et al. EHJ 2013){{Cite journal|last1=Mancia|first1=Giuseppe|last2=Fagard|first2=Robert|last3=Narkiewicz|first3=Krzysztof|last4=Redon|first4=Josep|last5=Zanchetti|first5=Alberto|last6=Böhm|first6=Michael|last7=Christiaens|first7=Thierry|last8=Cifkova|first8=Renata|last9=De Backer|first9=Guy|date=2013-07-01|title=2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)|journal=European Heart Journal|volume=34|issue=28|pages=2159–2219|doi=10.1093/eurheartj/eht151|issn=1522-9645|pmid=23771844|doi-access=free|hdl=1854/LU-4127523|hdl-access=free}}
• ESC/EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. (Ryden et al. EHJ 2013){{Cite journal|last1=Authors/Task Force Members|last2=Rydén|first2=Lars|last3=Grant|first3=Peter J.|last4=Anker|first4=Stefan D.|last5=Berne|first5=Christian|last6=Cosentino|first6=Francesco|last7=Danchin|first7=Nicolas|last8=Deaton|first8=Christi|last9=Escaned|first9=Javier|date=2013-10-01|title=ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)|journal=European Heart Journal|volume=34|issue=39|pages=3035–3087|doi=10.1093/eurheartj/eht108|issn=1522-9645|pmid=23996285|doi-access=free}}
• SC/ESA 2014 Guidelines on non-cardiac surgery: cardiovascular assessment and management. (Kristensen et al. EHJ 2014){{Cite journal|last1=Kristensen|first1=Steen Dalby|last2=Knuuti|first2=Juhani|last3=Saraste|first3=Antti|last4=Anker|first4=Stefan|last5=Bøtker|first5=Hans Erik|last6=Hert|first6=Stefan De|last7=Ford|first7=Ian|last8=Gonzalez-Juanatey|first8=Jose Ramón|last9=Gorenek|first9=Bulent|date=2014-09-14|title=2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)|journal=European Heart Journal|volume=35|issue=35|pages=2383–2431|doi=10.1093/eurheartj/ehu282|issn=1522-9645|pmid=25086026|doi-access=free}}
• Reporting on patient reported outcomes in cardiovascular trials – Position statement of the ESC cardiovascular round table. (Anker et al. EHJ 2014){{Cite journal|last1=Anker|first1=Stefan D.|last2=Agewall|first2=Stefan|last3=Borggrefe|first3=Martin|last4=Calvert|first4=Melanie|last5=Jaime Caro|first5=J.|last6=Cowie|first6=Martin R.|last7=Ford|first7=Ian|last8=Paty|first8=Jean A.|last9=Riley|first9=Jillian P.|date=2014-08-07|title=The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials|journal=European Heart Journal|volume=35|issue=30|pages=2001–2009|doi=10.1093/eurheartj/ehu205|issn=1522-9645|pmid=24904027|doi-access=free}}
• ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (Ponikowski et al., EHJ 2016){{Cite journal|last1=Ponikowski|first1=Piotr|last2=Voors|first2=Adriaan A.|last3=Anker|first3=Stefan D.|last4=Bueno|first4=Héctor|last5=Cleland|first5=John G. F.|last6=Coats|first6=Andrew J. S.|last7=Falk|first7=Volkmar|last8=González-Juanatey|first8=José Ramón|last9=Harjola|first9=Veli-Pekka|date=2016-07-14|title=2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC|journal=European Heart Journal|volume=37|issue=27|pages=2129–2200|doi=10.1093/eurheartj/ehw128|issn=1522-9645|pmid=27206819|doi-access=free}}
• Co-chair, Consensus Group “International Cachexia Definition – Update 2016” (ongoing)

Anker has been a member of more than 30 international clinical trial steering committees, chairing or co-chairing more than 10 (including the FAIR-HF,{{Cite web|url=https://www.wikijournalclub.org/wiki/FAIR-HF|title=FAIR-HF - Wiki Journal Club|last=LLC|first=Peripheral Brain|website=www.wikijournalclub.org|language=en|access-date=2017-05-17}} TIM-HF,{{cite journal|doi=10.1093/eurjhf/hfq199 | pmid=21098580 | volume=12 | issue=12 | title=Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design | journal=European Journal of Heart Failure | pages=1354–1362 | last1 = Koehler | first1 = Friedrich | year=2010| s2cid=32860744 | doi-access=free }} BACH,{{Cite journal|url=https://clinicaltrials.gov/ct2/show/NCT00537628|title=Biomarkers in Acute Heart Failure - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|date=30 July 2008 |language=en|access-date=2017-05-17}} AUGMENT-HF,{{Cite journal|last1=Anker|first1=Stefan D.|last2=Coats|first2=Andrew J. S.|last3=Cristian|first3=Gabriel|last4=Dragomir|first4=Dinu|last5=Pusineri|first5=Enrico|last6=Piredda|first6=Massimo|last7=Bettari|first7=Luca|last8=Dowling|first8=Robert|last9=Volterrani|first9=Maurizio|date=2015-09-07|title=A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)|journal=European Heart Journal|volume=36|issue=34|pages=2297–2309|doi=10.1093/eurheartj/ehv259|issn=1522-9645|pmc=4561351|pmid=26082085}} ACT-ONE,{{Cite journal|last1=Rosenfield|first1=Kenneth|last2=Matsumura|first2=Jon S.|last3=Chaturvedi|first3=Seemant|last4=Riles|first4=Tom|last5=Ansel|first5=Gary M.|last6=Metzger|first6=D. Chris|last7=Wechsler|first7=Lawrence|last8=Jaff|first8=Michael R.|last9=Gray|first9=William|date=2016-03-17|title=Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis|journal=New England Journal of Medicine|volume=374|issue=11|pages=1011–1020|doi=10.1056/NEJMoa1515706|issn=0028-4793|pmid=26886419|doi-access=free}} RESHAPE-HF2,{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT02444338|title=A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2017-05-17}} IMPULSE-HF,{{Cite web|url=http://www.impulse-dynamics.com/int/news/impulse-dynamics-announced-first-enrollment-impulse-hf-european-randomized-efficacy-study/|title=Impulse Dynamics announced the first enrollment in the IMPULSE-HF European Randomized Efficacy Study - INT|website=www.impulse-dynamics.com|language=en-INT|access-date=2017-05-17}} FAIR-HF2,{{Cite web|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000068-40/PT|title=Clinical Trials Register|website=www.clinicaltrialsregister.eu|access-date=2017-05-17}}{{Cite web|url=http://www.herzzentrum-goettingen.de/en/content/research/1980.html|title=Universitätsmedizin Göttingen - Innovative Clinical Trials|website=www.herzzentrum-goettingen.de|access-date=2017-05-17}} Fair-HFpEF, EMPORER-HFpEF trials{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT03057951|title=EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2017-05-17}}). He served in several data and safety monitoring boards (chairing five) and end-point committees (chairing three). In 2015 and again in 2016, he was named in the Thomson Reuters Highly Cited Researchers list.{{Cite news|url=http://hcr.stateofinnovation.com/|title=HCR Clarivate Analytics|access-date=2017-05-17|language=en}}

• 1998: "Ehrenmedaille der Charité Berlin" (honorary medal of Charité Medical School, Berlin){{cn|date=June 2024}}
• 2000: Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure.{{cn|date=June 2024}}
• 2006: Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia{{Cite report |url=http://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319457.pdf |title=Council on Clinical Cardiology: Scientific Sessions 2006 Highlights |date=November 2006 |page=19 |archive-url=https://web.archive.org/web/20161020181657/http://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319457.pdf |archive-date=2016-10-20}} {{Better source needed|reason=While the current source does reference the paper in question, it doesn't indicate the subject (Anker) as being involved. (WP:NOTRS).|date=June 2024}}
• 2007: Young Investigator Award of the European HF Association for the paper: Okonko D, Anker SD, Poole-Wilson PA. Epo and inflammatory cytokines in patients with chronic heart failure – mechanistic studies.{{cn|date=June 2024}}
• 2011: Storz German Telemedicine Award 2011 for TIM-HF (together with Köhler){{cn|date=June 2024}}

2018: Copernicus Award from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the Fundacja na rzecz Nauki Polskiej (FNP, Foundation for Polish Science)https://www.fnp.org.pl/en/laureaci-nagrody-copernicus-2018/ for services to German-Polish research collaboration{{Cite news|url=https://dzhk.de/en/news/latest-news/article/copernicus-award-2018-for-stefan-anker/|title=Copernicus Award 2018 for Stefan Anker|access-date=2018-11-08|language=en}}

{{Reflist}}

{{Authority control}}

{{DEFAULTSORT:Anker, Stefan D.}}

Category:1965 births

Category:Living people

Category:German cardiologists